Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136

PHASE3CompletedINTERVENTIONAL
Enrollment

475

Participants

Timeline

Start Date

October 1, 2008

Primary Completion Date

May 27, 2010

Study Completion Date

May 27, 2010

Conditions
MeaslesVaricellaMumpsRubella
Interventions
BIOLOGICAL

PriorixTM

Subcutaneous administration in left upper arm

BIOLOGICAL

VarilrixTM

Subcutaneous administration in right upper arm

BIOLOGICAL

Priorix-Tetra®

Subcutaneous injection in left upper arm

Trial Locations (13)

420-767

GSK Investigational Site, Bucheon-si

301-723

GSK Investigational Site, Daejeon

501-717

GSK Investigational Site, Gwangju

641-560

GSK Investigational Site, GyeongSangNam-do

570-711

GSK Investigational Site, Iksan

400-711

GSK Investigational Site, Incheon

561-712

GSK Investigational Site, Jeonju Jeonbuk

463-712

GSK Investigational Site, Seongnam-si, Gyeonggi-do

130-702

GSK Investigational Site, Seoul

150-719

GSK Investigational Site, Seoul

150-950

GSK Investigational Site, Seoul

480-130

GSK Investigational Site, Uijeongbu, Kyonggi-do

220-701

GSK Investigational Site, Wonju-si Kangwon-do

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY